Business
AI summaryOncopeptides AB is a biotech company engaged in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product is Pepaxti (melflufen), a drug conjugate with an alkylating payload developed to treat adults with multiple myeloma, built on its PDC platform that exploits the altered metabolism of cancer cells. The company also has candidates including OPD5, OPDC3, and Gliopep for hematological or solid tumors and glioblastoma, as well as its SPiKE platform designed to bind both NK-cells and specific cancer cell targets. Oncopeptides was incorporated in 2000 and is headquartered in Stockholm, Sweden.
